Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...

Trevi Therapeutics has finished enrolling subjects in a trial of investigational Haduvio for treating chronic cough in IPF ...

Trevi Therapeutics (TRVI)has completed enrollment in its Phase 2b CORAL trial of Haduvio for the treatment of chronic cough in patients with ...

A Corporate presentation is available for in-person conference attendees. About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the ...

Oppenheimer raised the firm’s price target on Trevi Therapeutics (TRVI) to $12 from $9 and keeps an Outperform rating on the shares. The firm ...

The business’s 50-day moving average price is $4.09 and its 200-day moving average price is $3.41. Trevi Therapeutics has a 12 month low of $2.30 and a 12 month high of $5.05. About Trevi ...

NEW HAVEN, Conn., Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral ...

Trevi Therapeutics (NASDAQ:TRVI – Get Free Report)‘s stock had its “buy” rating restated by research analysts at D. Boral Capital in a research note issued to investors on Monday ...

Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI ), a clinical-stage biopharmaceutical company developing the investigational therapy HaduvioTM (oral nalbuphine ER) for the ...

Drug maker Trevi Therapeutics (TRVI) is climbing 4.5% after investment bank Stifel raised its price target on the name to $12 from $8. Stifel maintained a Buy rating on the shares. Why Stifel Is ...